Key facts
- It has raised $13.9M; the latest was Later Stage VC ($15.0M) in Dec 2025.
- Notable investors include European Innovation Council (Belgium), Kindmore, ZEISS Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Perseus Biomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Perseus Biomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Perseus Biomics
Developer of a microbiome analysis technology designed to monitor the microbiome status and function, and quantify its impact on all aspects of human life. The company offers a benchtop device and microbiome profiling services using optical mapping-based technology, enabling researchers and clinicians to perform strain-level microbiome analysis with high sensitivity, specificity, and reproducibility.
- Sector
- Healthcare
- HQ
- Leuven, Belgium
- Founded
- 2016
- Employees
- 24
- Website
- perseusbiomics.com/
- Ownership
- Privately Held (backing)
Perseus Biomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Perseus Biomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Perseus Biomics in its N-PORT filings yet. We sweep new filings monthly.